Invention Grant
US08551474B2 Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
有权
使用表达α(1,3) - 半乳糖转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种
- Patent Title: Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
- Patent Title (中): 使用表达α(1,3) - 半乳糖转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种
-
Application No.: US12890178Application Date: 2010-09-24
-
Publication No.: US08551474B2Publication Date: 2013-10-08
- Inventor: Charles J. Link, Jr. , Tatiana Seregina , Gabriela Rossi
- Applicant: Charles J. Link, Jr. , Tatiana Seregina , Gabriela Rossi
- Applicant Address: US IA Des Moines
- Assignee: Central Iowa Health System
- Current Assignee: Central Iowa Health System
- Current Assignee Address: US IA Des Moines
- Agency: Cooley LLP
- Main IPC: A01N63/00
- IPC: A01N63/00 ; A01N63/02 ; C12N5/09 ; C12N5/10 ; C12N5/02 ; C12N5/07 ; A61K35/00

Abstract:
The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
Public/Granted literature
- US20110086067A1 ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE Public/Granted day:2011-04-14
Information query